The Australian biotech company, ImmVirX, specializes in developing novel oncolytic viruses that selectively infect and kill cancer cells while inducing a systemic anti-tumor immune response. By harnessing the power of bio-selected RNA viruses, ImmVirX aims to enhance the effectiveness of current immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies. Their focus is on targeting cancer indications with high unmet needs, particularly in the field of oncology, immuno-oncology, and colorectal cancer. Founded in 2019, ImmVirX is based in New Lambton Heights, Australia.